HLA Compatibility Requirements for CD8 -T-Cell-Mediated Suppression of Human Immunodeficiency Virus Replication

Size: px
Start display at page:

Download "HLA Compatibility Requirements for CD8 -T-Cell-Mediated Suppression of Human Immunodeficiency Virus Replication"

Transcription

1 JOURNAL OF VIROLOGY, Dec. 1998, p Vol. 72, No X/98/$ Copyright 1998, American Society for Microbiology. All Rights Reserved. HLA Compatibility Requirements for CD8 -T-Cell-Mediated Suppression of Human Immunodeficiency Virus Replication CARL E. MACKEWICZ, 1 MARVIN R. GAROVOY, 2 AND JAY A. LEVY 1 * Department of Medicine 1 and Immunogenetics and Transplantation Laboratory, Department of Surgery, 2 School of Medicine, University of California, San Francisco, San Francisco, California Received 14 July 1998/Accepted 1 September 1998 CD8 T cells from human immunodeficiency virus (HIV)-infected individuals can suppress HIV replication in cultured CD4 cells by a noncytotoxic mechanism. Efficient suppression of HIV replication (>90% reduction) does not require HLA class I or class II histocompatibility between the effector CD8 T cells and the infected target CD4 T cells. However, maximal control of HIV production occurs when the CD8 effector cells and CD4 target cells are syngeneic. In some cases, more than 20-fold fewer syngeneic CD8 T cells were required to achieve the same degree of HIV inhibition as HLA-mismatched CD8 T cells. The increased antiviral activity seen in the syngeneic setting did not map exclusively to either the HLA class I or class II locus. These findings suggest that genetic compatibility (potentially, but not necessarily, at the HLA class I and class II loci) regulates CD8 T-cell noncytotoxic antiviral activity against infected CD4 T cells. CD8 T cells from healthy human immunodeficiency virus (HIV)-infected individuals can suppress HIV replication in cultured CD4 T cells without any apparent killing of infected cells (16, 28). This noncytotoxic CD8 -cell antiviral response is detected by a reduction in HIV p24 antigen and/or reverse transcriptase (RT) levels in culture fluids upon mixing CD8 T cells with the infected target CD4 T cells. This cellular immune response can suppress replication of HIV type 1 (HIV- 1), HIV-2, and simian immunodeficiency virus (references 16 and 29 and unpublished observations) and has been observed in several species of nonhuman primates (2, 6, 8, 13, 23). Unlike the antigen-specific cytotoxic mechanism of HLA class I-restricted CD8 cytotoxic T lymphocytes (CTL), the CD8 -T-cell noncytotoxic anti-hiv activity does not appear to require HLA compatibility to effectively control HIV replication (17). Although initial evidence suggested a more efficient control of HIV in autologous settings (27, 28), a number of laboratories have shown that CD8 cells (polyclonal or clonal) can efficiently inhibit HIV replication (by 90%) in heterologous peripheral blood mononuclear cells (PBMC) or CD4 T cells (1, 3, 16, 20, 26, 28, 29). Importantly, the antiviral activity in these heterologous systems does not seem to be dependent on alloreactivity between the CD4 target cells and the CD8 effector cells (29). To determine if HLA genetics regulate this type of cellular anti-hiv response, we investigated the HLA compatibility requirements for efficient control of HIV replication by CD8 T cells. The results suggest that the extent of this antiviral CD8 - T-cell noncytotoxic response is dependent on the genetic relatedness between the effector and target cells, but not necessarily on HLA class I or class II determinants. * Corresponding author. Mailing address: Department of Medicine, School of Medicine, University of California, San Francisco, San Francisco, CA Phone: (415) Fax: (415) jalevy@itsa.ucsf.edu. Present address: Xoma Corporation, Berkeley, CA MATERIALS AND METHODS Subjects. Heparinized peripheral blood samples were obtained by venipuncture from HIV-1-seropositive and -seronegative donors. Among these, two pairs of identical twins, discordant for HIV infection, were studied. The HIV-infected twins were clinically healthy, with CD4 -T-cell counts of around 400/ l (14 to 16%) in one case and just over 300/ l (24 to 26%) in the other. Both individuals have been infected for over 10 years. In addition, cells from four other longterm-asymptomatic HIV-infected subjects were studied. Their CD4 -T-cell counts ranged from 319 to 940 cells/ l (23 to 36%). Blood samples from HIVseronegative donors were obtained from laboratory volunteers or were provided by Irwin Memorial Blood Centers (San Francisco, Calif.). The study received the approval of the Committee on Human Research, University of California, San Francisco. Assay for CD8 -cell noncytotoxic antiviral activity. Purified CD4 cells isolated from uninfected (or, in some cases, infected) blood donors were stimulated and acutely infected with HIV-1 as described previously (20). In brief, the CD4 cells, purified with anti-cd4 immunomagnetic beads (Dynal, Lake Success, N.Y.), were cultured for 3 days with 3 g of phytohemagglutinin (PHA) (Sigma Chemical Co., St. Louis, Mo.)/ml in RPMI 1640 medium containing 2 mm glutamine, 1% antibiotics (100 U of penicillin/ml, 100 g of streptomycin/ml), 10% heat-inactivated (56 C; 30 min) fetal calf serum, and 100 U of human recombinant interleukin 2 (Collaborative Research, Bedford, Mass.)/ml. In each case, the purity of the CD4 -cell populations was 95% or greater and 95% were CD3 as assessed by flow cytometric analysis (15). The stimulated cells were then washed and treated with Polybrene (2 g/ml for 30 min at 37 C) and subsequently acutely infected with % tissue culture infective doses of HIV-1 SF33. This virus is a highly cytopathic strain (25) and is not sensitive to the antiviral effects of -chemokines (18). After 1hofincubation with virus at 37 C, the cells were washed and resuspended in the RPMI 1640 growth medium. This method of infection routinely yields 15 to 35% HIV antigen-positive cells as detected by immunofluorescence at the peak of HIV replication (5 to 7 days) (20). Immediately after the 1-h virus inoculation, the CD4 cells were cultured with various amounts of CD8 cells previously purified from an HIV-infected subject s PHA-stimulated PBMC by using anti-cd8 immunomagnetic beads as described previously (20). The amount of HIV replication in the cultures was measured by a standard particle-associated RT assay (10). The extent of CD8 - cell antiviral activity (indicated by the percent suppression of HIV replication) was determined by comparison to the amount of RT activity in culture fluids of infected CD4 cells grown alone. HLA typing for class I and class II antigens. The subjects HLA class I phenotypes were determined by serologic or molecular methods. Class I antigens were detected by the use of the standard microlymphocytotoxicity technique (11), while the genetic alleles were determined by DNA-typing techniques, using sequence-specific primers (5, 21). The HLA class II phenotype was determined by similar molecular methods

2 10166 MACKEWICZ ET AL. J. VIROL. TABLE 1. HLA class I and class II phenotypes of effector and target cells studied Cell type Subject HIV status Class I phenotype a Class II phenotype b Effector c T1A Infected A3 A29 B44 B51 DR7 DR11 DQ2 DQ7 T2A Infected A2 A3 B14 B51 DR2 DR11 DR52 DQ1 DQ7 Target d T1B (T1A twin) Seronegative A3 A29 B44 B51 DR7 DR11 DQ2 DQ7 T2B (T2A twin) Seronegative A2 A3 B14 B51 DR2 DR11 DR52 DQ1 DQ7 S1 Seronegative A24 Ax B27 B61 CW3 CW7 DR14 DR15 DQ5 S2 Seronegative A1 A24 B35 B37 CW4 DR10 DR11 DQ5 DQ7 S3 Seronegative A2 A30 B13 B62 CW6 DR11 DR14 DQ5 DQ7 S4 Seronegative A2 A24 B51 B61 CW3 DR2 DR4 DQ1 DQ3 S5 Seronegative A11 A31 B51 B60 CW3 DR4 DR9 DQ3 a Determined by serological typing as described in Materials and Methods. b Determined by molecular methods as described in Materials and Methods. c Purified CD8 cells isolated from PHA-stimulated PBMC. d Purified CD4 cells that had been PHA stimulated for 3 days and then infected with HIV-1 SF33. RESULTS HLA compatibility requirements: HIV-discordant identical twins. (i) Genetic similarity confers maximal suppression of HIV. The relative degree of antiviral activity of CD8 T cells from healthy HIV-infected individuals was assessed by using experimentally infected CD4 T cells of differing genetic relatedness to the effector cells (Table 1). We first analyzed HLA compatibility requirements with CD4 cells from seronegative donors as targets and CD8 cells from two pairs of HIVdiscordant monozygotic twins. Thus, in one case, PHA-stimulated CD8 T cells from subject T1A were cocultured at various input ratios with HIV-1 SF33 -infected CD4 T cells that were syngeneic (from subject T1A s uninfected twin, subject T1B), HLA mismatched in the class I and II loci, or mismatched in only the class I or class II locus. The highest degree of HIV suppression was observed when syngeneic infected target CD4 T cells were used (Fig. 1A). Almost-complete inhibition of HIV replication (97% reduction) was seen at the lowest CD8 -cell/cd4 -cell ratio tested (0.25). In contrast, in cultures of completely mismatched cells, only half the suppression of HIV replication (48%) occurred at the same CD8 - cell/cd4 -cell ratio (0.25). From a different perspective, even at the CD8 -cell/cd4 -cell ratio of 2.0, HIV suppression in HLA class I- and class II-mismatched CD4 T cells did not reach the level of that observed when syngeneic target cells were used at the CD8 /CD4 cell ratio of 0.25 (88 versus 99%, respectively). Thus, greater than eightfold more CD8 T cells were required to inhibit HIV replication in HLA-unrelated CD4 T cells than in HLA-identical CD4 T cells. The extent of CD8 -cell inhibition of HIV production by target cells that were mismatched at only the class I or only the class II locus was intermediate to those observed with completely mismatched and syngeneic cultures (Fig. 1A). In these studies, CD8 -cell/cd4 -cell ratios of 1.0 or more were required to achieve 95% suppression of HIV replication. No consistent difference in the extent of suppression was noted whether the effector and target cells were mismatched in the class I or the class II region (Fig. 1A). CD8 cells from the seronegative twin T1B did not suppress HIV production from his own experimentally infected CD4 cells nor from the CD4 cells of a genetically unrelated subject at any CD8 -cell/cd4 -cell ratio tested (data not shown). These results indicated that HLA histocompatibility by itself is not sufficient to confer HIV-suppressing activity on mitogenstimulated CD8 cells and that if allogeneic responses are occurring in these short-term cultures, they do not induce CD8 cells from uninfected people to block HIV production. Similar results with anti-hiv responses were observed with CD8 cells from a different set of twins, T2A and T2B (Fig. 1B). Again, potent antiviral activity was seen in the syngeneic setting. In contrast, 32-, 16-, 8-, and 8-fold more CD8 cells were needed to achieve the same level of suppression of virus replication in CD4 cells that were class I and II mismatched, class I mismatched, class II mismatched, or class I and class II partially mismatched, respectively (Fig. 1B). (ii) Genetic regulatory effect is not dependent on in vitro activation of CD8 cells. To further evaluate the extent to which HLA genetics regulate CD8 -cell antiviral responses, analogous experiments were performed with CD8 cells that were not previously mitogen activated (as opposed to the experiments described above). As with mitogen-stimulated CD8 cells, the most efficient control by unstimulated CD8 cells was observed against syngeneic CD4 cells (Fig. 1C). Unstimulated CD8 cells showed less antiviral activity against target cells that were mismatched at class I, class II, or both loci. Results with CD4 target cells from HIV-infected subjects. In order to further establish the significance of these findings, CD8 cells from four additional HIV-infected subjects were evaluated. Because no other twins discordant for HIV infection were available, syngeneic target cells could only be obtained by using autologous CD4 cells. Thus, CD4 cells from HIV-infected subjects of different HLA relatedness were experimentally infected with HIV-1 and used as target cells (Table 2). Typically, endogenous virus is not released into culture at appreciable levels until 12 days poststimulation (unpublished observations). It is, therefore, unlikely that endogenous virus contributes much to the total peak HIV replication measured (on day 6 or 9) in these cultures. Reciprocal pairings of effector and target cells were performed to control for possible variations in the replicative capacity of the different CD4 -cell populations used. In agreement with the above-mentioned results obtained with CD4 target cells from HIV-seronegative donors, maximal CD8 -cell-mediated suppression was observed when the effector and target cells were syngeneic (Fig. 2). For example, in the experiments with S6 CD8 cells (Fig. 2A), 80% suppression of HIV replication was seen against autologous (syngeneic) infected CD4 cells at the CD8 -cell/cd4 -cell ratio of 0.1. When class I-mismatched (S7 CD4 cells with two class II DQ alleles shared) or class II-mismatched (T1A CD4 cells with one class I A and one class I B allele shared) targets were used, 80% suppression was not observed until a CD8 -cell/ CD4 -cell ratio of 0.5 and 1.0, respectively, was reached. The lowest extent of CD8 -cell-mediated suppression occurred

3 VOL. 72, 1998 HLA COMPATIBILITY AND CD8 -CELL NONCYTOTOXIC RESPONSE FIG. 1. Extent of CD8 -T-cell anti-hiv activity exhibited against HIV replication in CD4 T cells of different genetic relatedness. The anti-hiv activities of PHA-stimulated CD8 T cells from two HIV-infected twins, T1A (A) and T2A (B), and unstimulated T1A CD8 T cells (C) were titrated against HIV- 1 SF33 -infected CD4 T cells from their respective syngeneic twins, an HLA class I- and II-mismatched subject, HLA class I-mismatched subjects, and HLA class II-mismatched subjects. The amount of antiviral activity exhibited (% suppression of HIV) reflects the extent of reduction in RT activity in the cell culture fluid compared to the activity in the respective infected CD4 T cells cultured alone. ND, not done. The peak amounts of HIV replication (RT activity on day 6) in the control T1B, S1, S2, S3, and S4 CD4 cell cultures (A and C) were , , , , and cpm/ml, respectively. The amounts of HIV production in the T2B, S1, S2, S5, and T1B CD4 target cells (B) were , , , , and cpm/ml, respectively. These results are representative of two separate experiments with each twin, including additional examples of class II- and class I/class II partially mismatched cells. when the effector and target cells were completely unrelated in both the class I and class II loci (e.g., S9 CD4 cells). In this case, 80% suppression of HIV replication occurred at the CD8 -cell/cd4 -cell ratio of 2.0 (data not shown). These results indicated that about 20-fold more CD8 cells were required to achieve the same amount of suppression as that seen in the syngeneic setting. Similar results were obtained with the other subjects CD8 cells studied (Fig. 2B to E). Of the five data sets analyzed, the highest extent of suppression was observed in the syngeneic setting except in one case (i.e., 1 of 11 mismatches tested). In that case, the effector and target cells were mismatched in the class II locus (T1A CD8 cells versus S6 CD4 cells [Fig. 2C]). In general, the smallest amount of suppression occurred when the effector and target cells were class I and class II disparate or were similar at only one class II allele. No consistent difference in suppressing activity between class I- and class II-related pairings was observed. In some cases, class I mismatches showed better suppression than class II mismatches and vice versa. Because the sample number for each group was small, no statistical significance was attained. However, if all the mismatched pairings are taken as a group, then CD8 cells showed significantly better suppressing activity in the syngeneic setting when analyzed with a stratified Wilcoxon rank sum test, the strata being the effector cell phenotypes (P 0.035). Nevertheless, in all cases, regardless of the extent of HLA dissimilarity between the CD8 and CD4 cells, 50% suppression ( 80% in 8 of 11 cases) could be achieved if sufficient CD8 cells were added, i.e., to yield a CD8 -cell/ CD4 -cell ratio of 1.0 or 2.0 (data not shown). HIV replication in all target cell populations reached comparable levels (Fig. 2), and the different target cells were comparably sensitive to CD8 -cell-mediated suppression (as seen in the syngeneic setting), except, possibly, for S8 CD4 cells. The S8 CD4 cells showed greater sensitivity to suppression mediated by S7 and T1A CD8 cells (both mismatched) than to that mediated by syngeneic S8 CD8 cells. Furthermore, S8 CD8 cells have previously been shown to have relatively low antiviral activity (unpublished observations). Together, these results suggest that the relatively weak suppressing activity of S8 CD8 cells (Fig. 2E) is probably not due to an insensitivity of S8 CD4 cells to CD8 -cell-mediated suppression. Analysis of reciprocal pairings among subjects effector and target cells. With the experimental data shown in Fig. 2, analysis of reciprocal pairings of effector and target cells (including mismatches at class I, class II, or both loci) revealed no consistent pattern of genetic regulation (Fig. 3). The CD8 -cell antiviral activity in one direction was usually markedly different than that in the opposite direction, even when the data was standardized for the intrinsic (maximal) level of an individual s CD8 -cell antiviral activity (i.e., that seen in the syngeneic setting). This finding was made even though three pairings involved the same target cells (S6 CD4 cells). For example, in one case, S6 CD8 cells controlled HIV replication in the S7 mismatched CD4 cells an average of fivefold more than S7 CD8 cells controlled virus production in S6 CD4 cells. In the two other reciprocal cases involving S6 cells (with T1A and S9), the opposite was true (about seven- and twofold less suppression, respectively). DISCUSSION CD8 T cells from HIV-infected individuals suppress HIV replication in acutely infected CD4 T cells (reviewed in reference 16). The present studies indicate that maximal CD8 - cell suppression of HIV replication in culture is achieved when the infected CD4 target cells and the effector CD8 T cells are syngeneic, and thus share the same HLA class I and II genotype. Mismatches in the class I as well as the class II locus resulted in less efficient control of HIV by antiviral CD8 T cells, but possibly better than that in the completely mismatched setting. The results suggest that genetic relatedness between CD8 cells and CD4 cells influences the extent of CD8 -cell anti-hiv activity and that, unlike classic CD8 -cell cytolytic activity, this response is not class I restricted.

4 10168 MACKEWICZ ET AL. J. VIROL. TABLE 2. HLA class I and class II phenotypes of effector a and target b cells studied Subject HIV status Class I phenotype c Class II phenotype d T1A Infected A3 A29 B44 B51 C15 C16.1 DR7.1 DR11.4 DQA2 DQA5 DQB2 DQB3.1 S6 Infected A2.1 A29 B51 B53 C4 C14 DR1.2 DR8.1 DQA1.1 DQA4.1 DQB4.2 DQB5.1 S7 Infected A3 A26 B27 B57 C2 C6.2 DR1.1 DR13 DQA1.1 DQA1.3 DQB5.1 DQB6.3 S8 Infected A2.1 A24 B15 B49 C3.4 C7 DR4.7 DR13 DQA1.2 DQA3 DQB3.1 DQB6.4 S9 Infected A3 A25.1 B7 B39 C7 C12.3 DR11.1 DR15.1 DQA1.2 DQA5.1 DQB3.1 DQB6.2 a Purified CD8 cells isolated from PHA-stimulated PBMC. b Purified CD4 cells that had been PHA-stimulated for 3 days and then infected with HIV-1 SF33. c Determined by molecular methods as described in Materials and Methods. d Determined by molecular methods as described in Materials and Methods. The DR alleles shown indicate the alleles from the HLA-DRB1 locus. Of six different HIV-infected subjects CD8 cells studied, nearly all suppressed HIV replication better in syngeneic infected CD4 cells than in any of the mismatched CD4 -cell settings (Fig. 1 and 2). The increased suppressing activity in the syngeneic setting was reflected by a higher percent suppression of HIV at various CD8 -cell/cd4 -cell ratios (most prominently at the low ratios) or by a lower number of CD8 cells required to achieve a certain level of HIV suppression (i.e., 4- FIG. 2. Extent of CD8 -T-cell anti-hiv activity exhibited against HIV replication in CD4 T cells of different genetic relatedness. The anti-hiv activities of PHA-stimulated CD8 T cells from various HIV-infected subjects were titrated against HIV-1 SF33 -infected CD4 T cells from the subjects themselves (syngeneic), HLA class I-mismatched subjects, and HLA class II-mismatched subjects. The amount of antiviral activity exhibited by the CD8 cells (% suppression of HIV) reflects the extent of reduction in RT activity in the cell culture fluid compared to the activity seen in the respective infected CD4 T cells cultured alone. The average peak amounts of HIV replication (RT activity) in the control T1A, S6, S7, S8, and S9 CD4 cell cultures were , , , , and cpm/ml, respectively. All cultures were set up in triplicate.

5 VOL. 72, 1998 HLA COMPATIBILITY AND CD8 -CELL NONCYTOTOXIC RESPONSE FIG. 3. Comparison of the relative CD8 -cell suppressing activities in reciprocal pairings of CD8 and CD4 cells. The extent of relative CD8 -cell suppressing activity was calculated for each case shown in Fig. 2 where the antiviral activity of one subject s CD8 cells was assessed against another subject s infected CD4 cells and vice versa. For a given subject s CD8 cells, the quotient of (RT activity in the mismatched culture)/(rt activity in the respective syngeneic culture) was obtained for the CD8 -cell/cd4 -cell ratios of 0.1, 0.25, and 0.5. These values were then averaged to yield a representative level of CD8 -cell suppressing activity relative to that measured in the respective syngeneic setting (the intrinsic CD8 -cell activity). In this fashion, the extent of antiviral activity of one subject s CD8 cells could be compared directly to that of another subject s CD8 cells without concern for the potential differences between the individuals intrinsic CD8 -cell functions. to 20-fold fewer CD8 cells needed to suppress HIV by 80%). This genetic compatibility effect was independent of whether the target cells used were from HIV-seropositive (Fig. 2) or -seronegative (Fig. 1) donors, and it does not appear to be due to differences in CD4 -cell HIV-replicative capacity or sensitivity to CD8 -cell-mediated suppression. While totally mismatched effector and target cells may have resulted in the smallest amount of HIV suppression, we cannot conclude that relatedness at class I or class II conferred a statistically significant increase in antiviral activity. Furthermore, no consistent difference in the extent of suppression was seen between class I-related and class II-related settings, albeit the number of shared alleles was never more than two and in several cases was only one (Fig. 1 and 2). The similar pattern of suppressing activity seen when freshly isolated (non-exogenously stimulated) CD8 cells were used suggests that this apparent genetic control of noncytolytic antiviral activity is not dependent on mitogen stimulation (Fig. 1C). This finding may be the consequence of the highly activated nature of CD8 T cells in HIV-infected individuals (15). This type of CD8 -cell noncytolytic anti-hiv response appears to result from a block in viral transcription (16, 19). The findings of this study imply that genetic compatibility in some way either enhances this mechanism for controlling HIV or provides for the activity of an additional type of antiviral mechanism that is genetically restricted. Both possibilities would be consistent with the observation that, even if the effector and target cells are totally HLA mismatched, efficient HIV suppression can be achieved if a high enough CD8 effector cell input is used (Fig. 1 and 2). Since a -chemokine-insensitive HIV isolate was used in the present study, involvement of chemokine-mediated antiviral effects (7) are not likely. Furthermore, because CD8 T cells do not produce type 1 interferons (unpublished observations) and gamma interferon does not have anti-hiv activity in HIV-infected CD4 T cells (20a), interferons are not likely to be responsible for the higher suppressing activity seen in HLA-matched settings. Cytotoxic activity is an obvious antiviral mechanism worth consideration. Many studies addressing this issue provide evidence that cytotoxicity is not responsible for the control of HIV replication in the autologous (or heterologous) systems used to study CD8 cell suppression of HIV production. Infected cells are not eliminated by the CD8 cells (9, 14, 19, 28, 30), nor is there cytolytic release of chromium-51 from autologous target cells (22, 26). In addition, the low CD8 -cell/cd4 - cell ratios (0.25 in the syngeneic setting) required to block HIV replication ( 90% suppression) are well below that seen for polyclonal or even clonal CTL (12). Even if only 10% of the CD4 cells were initially infected in our assays, the actual effector/target cell ratio would be 2.5 if every CD8 cell was an effector cell, which was likely not the case. Finally, HIV-specific CD8 CTL are exclusively class I restricted (12). The suppressing activity we observed was not genetically restricted at high CD8 -cell inputs, nor was it strictly class I restricted at lower inputs. In four of four cases in which the CD8 cells and CD4 cells were mismatched at class I (sharing one or two alleles at class II), a higher degree of suppression was observed relative to the completely mismatched setting (Fig. 1 and 2). Further analysis is required to determine specifically what role, if any, is played by class I or class II antigens in the increased suppressing activity seen in the syngeneic setting. Another possible explanation for the present findings is that the lower activity seen in the HLA-mismatched cases reflects allostimulatory signals that result in either up-regulation of HIV replication in the target CD4 cells (hence, less apparent suppression) or down-regulation of CD8 -cell antiviral activity. Allogeneic activity can involve either class I or class II antigens (24) and thus would not necessarily be restricted to either locus. The findings of Bruhl et al. (4) showing that allogeneic stimulation of CD8 cells can induce HIV-suppressive activity would seem to argue against the latter possibility. Preliminary studies addressing the former possibility indicate that a slight enhancement of HIV replication can occur upon exposure of the infected CD4 cells to a high input of allogeneic CD8 cells that lack antiviral activity, but not to the extent that could explain the difference in CD8 -cell activity we have observed (unpublished observations). In addition, the results from the reciprocal pairings (Fig. 3) showing marked differences in the extent of suppression from one direction to the other are not entirely consistent with allogeneic recognition being the sole regulating factor, since in all the cases that involved nonsyngeneic matches, most or all of the HLA alleles were allogeneic. In summary, HIV-infected individuals possess CD8 cells that can efficiently suppress HIV replication in HLA-unrelated CD4 lymphocytes. However, control of HIV production is maximal in a syngeneic setting regardless of whether or not the CD8 cells are mitogen stimulated. This control does not appear to be strictly restricted to either the class I or class II locus, leaving a question as to whether a nonclassical antigen recognition process is involved. The findings suggest that many of the heterologous-cell assay systems employed to measure CD8 -T-cell-mediated noncytotoxic suppression of HIV replication are likely underestimating the relative degree of potential antiviral activity in the host. Furthermore, these studies emphasize the importance of considering the genetic relatedness between the effector and target cells when studying mechanistic issues and when quantitating and comparing noncytotoxic CD8 -T-cell antiviral activity. A better understanding of the regulation of this CD8 -T-cell anti-hiv activity could lead to improving or at least maintaining this antiviral response.

6 10170 MACKEWICZ ET AL. J. VIROL. ACKNOWLEDGMENTS These studies were funded by a grant from the NIH (RO1 AI30350) and the Histocompatibility Fund (M.R.G.). C.E.M. was supported in part by the University of California, San Francisco, AIDS Clinical Research Center (funded by the University of California Universitywide AIDS Research Program). We thank Roland Orque and Susan Ridha for their technical assistance and Christine Beglinger and Ann Murai for help in preparation of the manuscript. REFERENCES 1. Barker, T. D., D. Weissman, J. A. Daucher, K. M. Roche, and A. S. Fauci Identification of multiple and distinct CD8 T cell suppressor activities. J. Immunol. 156: Blackbourn, D. J., C. P. Locher, B. Ramachandran, S. W. Barnett, K. K. Murthy, K. D. Carey, K. M. Brasky, and J. A. Levy CD8 cells from HIV-2-infected baboons control HIV replication. AIDS 11: Brinchmann, J. E., G. Gaudernack, and F. Vartdal CD8 T cells inhibit HIV replication in naturally infected CD4 T cells: evidence for a soluble inhibitor. J. Immunol. 144: Bruhl, P., A. Kerschbaum, K. Zimmermann, M. M. Eibl, and J. W. Mannhalter Allostimulated lymphocytes inhibit replication of HIV type 1. AIDS Res. Hum. Retroviruses 12: Bunce, M., C. J. Taylor, and K. W. Welsh Rapid HLA-DQB typing by eight polymerase chain reaction amplifications with sequence specific primers (PCR-SSP). Hum. Immunol. 37: Castro, B. A., C. M. Walker, J. W. Eichberg, and J. A. Levy Suppression of human immunodeficiency virus replication by CD8 cells from infected and uninfected chimpanzees. Cell. Immunol. 132: Cocchi, F., A. L. DeVico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso Identification of RANTES, MIP-1alpha, and MIP-1beta as the major HIV-suppressive factors produced by CD8 T cells. Science 270: Ennen, J., H. Findeklee, M. T. Dittmar, S. Norley, M. Ernst, and R. Kurth CD8 T lymphocytes of African green monkeys secrete an immunodeficiency virus-suppressing lymphokine. Proc. Natl. Acad. Sci. USA 91: Gomez, A. M., F. M. Smaill, and K. L. Rosenthal Inhibition of HIV replication by CD8 T cells correlates with CD4 counts and clinical stage of disease. Clin. Exp. Immunol. 97: Hoffman, A. D., B. Banapour, and J. A. Levy Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 147: Hopkins, K. A Basic lymphocytotoxicity test, p In A. Zachary and G. A. Teresi (ed.), ASHI laboratory manual, 2nd ed., vol American Society for Histocompatibility and Immunogenetics, Lenexa, Kans. 12. Johnson, R. P., and B. Walker Cytotoxic T lymphocytes in HIV infection: responses to structural proteins. Curr. Opin. Microbiol. Immunol. 189: Kannagi, M., L. V. Chalifoux, C. I. Lord, and N. L. Letvin Suppression of simian immunodeficiency virus replication in vitro by CD8 lymphocytes. J. Immunol. 140: Kinter, A. L., S. M. Bende, E. C. Hardy, R. Jackson, and A. S. Fauci Interleukin 2 induces CD8 T cell-mediated suppression of human immunodeficiency virus replication in CD4 T cells and this effect overrides its ability to stimulate virus expression. Proc. Natl. Acad. Sci. USA 92: Landay, A. L., C. Mackewicz, and J. A. Levy An activated CD8 T cell phenotype correlates with anti-hiv activity and asymptomatic clinical status. Clin. Immunol. Immunopathol. 69: Levy, J. A., C. E. Mackewicz, and E. Barker Controlling HIV pathogenesis: the role of noncytotoxic anti-hiv activity of CD8 cells. Immunol. Today 17: Mackewicz, C., and J. A. Levy CD8 cell anti-hiv activity: nonlytic suppression of virus replication. AIDS Res. Hum. Retroviruses 8: Mackewicz, C. E., E. Barker, G. Greco, G. Reyes-Teran, and J. A. Levy Do -chemokines have clinical relevance in HIV infection? J. Clin. Investig. 100: Mackewicz, C. E., D. J. Blackbourn, and J. A. Levy CD8 cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc. Natl. Acad. Sci. USA 92: Mackewicz, C. E., H. W. Ortega, and J. A. Levy CD8 cell anti-hiv activity correlates with the clinical state of the infected individual. J. Clin. Investig. 87: a.Mackewicz, C. E., H. Ortega, and J. A. Levy Effect of cytokines on HIV replication in CD4 lymphocytes: lack of identity with the CD8 cell antiviral factor. Cell. Immunol. 153: Olerup, O., and H. Zetterquist HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours. Tissue Antigens 39: Paliard, X., A. Y. Lee, and C. M. Walker RANTES, MIP-1 and MIP-1 are not involved in the inhibition of HIV-1 SF33 replication mediated by CD8 T-cell clones. AIDS 10: Powell, J. D., T. Yehuda-Cohen, F. Villinger, H. M. McClure, K. W. Sell, and A. Ahmed-Ansari Inhibition of SIV-SMM replication in vitro by CD8 cells from SIV/SMM infected seropositive clinically asymptomatic sooty mangabeys. J. Med. Primatol. 19: Sherman, L. A., and S. Chattopadhyay The molecular basis of allorecognition. Annu. Rev. Immunol. 11: Tateno, M., and J. A. Levy MT-4 plaque formation can distinguish cytopathic subtypes of the human immunodeficiency virus (HIV). Virology 167: Toso, J. F., C. H. Chen, J. R. Mohr, L. Piglia, C. Oei, G. Ferrari, M. L. Greenberg, and K. J. Weinhold Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J. Infect. Dis. 172: Tsubota, H., C. I. Lord, D. I. Watkins, C. Morimoto, and N. L. Letvin A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J. Exp. Med. 169: Walker, C. M., D. J. Moody, D. P. Stites, and J. A. Levy CD8 lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234: Walker, C. M., G. A. Thomson-Honnebier, F. C. Hsueh, A. L. Erickson, L.-Z. Pan, and J. A. Levy CD8 T cells from HIV-1-infected individuals inhibit acute infection by human and primate immunodeficiency viruses. Cell. Immunol. 137: Wiviott, L. D., C. M. Walker, and J. A. Levy CD8 lymphocytes suppress HIV production by autologous CD4 cells without eliminating the infected cells from culture. Cell. Immunol. 128:

Suppression of HIV replication by lymphoid tissue CD8 cells correlates with the clinical state of HIV-infected individuals

Suppression of HIV replication by lymphoid tissue CD8 cells correlates with the clinical state of HIV-infected individuals Proc. Natl. Acad. Sci. USA Vol. 93, pp. 13125 13130, November 1996 Immunology Suppression of HIV replication by lymphoid tissue CD8 cells correlates with the clinical state of HIV-infected individuals

More information

Primary CD8 cells from HIV-infected individuals can suppress productive infection of macrophages independent of -chemokines

Primary CD8 cells from HIV-infected individuals can suppress productive infection of macrophages independent of -chemokines Proc. Natl. Acad. Sci. USA Vol. 95, pp. 1725 1729, February 1998 Immunology Primary CD8 cells from HIV-infected individuals can suppress productive infection of macrophages independent of -chemokines EDWARD

More information

CD8+ Cell Anti-HIV Activity Rapidly Increases Upon Discontinuation of Early Antiretroviral Therapy

CD8+ Cell Anti-HIV Activity Rapidly Increases Upon Discontinuation of Early Antiretroviral Therapy J Clin Immunol (9) 29:311 318 DOI 1.7/s1875-9-9275-y CD8+ Cell Anti-HIV Activity Rapidly Increases Upon Discontinuation of Early Antiretroviral Therapy M. Scott Killian & Jeremy Roop & Sharon Ng & Frederick

More information

Initiation of Human Immunodeficiency Virus Type 1 (HIV-1) Transcription is Inhibited by Noncytolytic CD8 + Suppression

Initiation of Human Immunodeficiency Virus Type 1 (HIV-1) Transcription is Inhibited by Noncytolytic CD8 + Suppression The Open Virology Journal, 2007, 1, 1-7 1 Initiation of Human Immunodeficiency Virus Type 1 (HIV-1) Transcription is Inhibited by Noncytolytic CD8 + Suppression R. Glenn Overman 1,, Anthony L. Llorens

More information

Differential gene expression in CD8 cells exhibiting noncytotoxic anti-hiv activity

Differential gene expression in CD8 cells exhibiting noncytotoxic anti-hiv activity Available online at www.sciencedirect.com R Virology 311 (2003) 400 409 www.elsevier.com/locate/yviro Differential gene expression in CD8 cells exhibiting noncytotoxic anti-hiv activity Leyla S. Diaz,

More information

require HLA compatibility at the effector phase. This inhibition of HIV replication is mediated by soluble factor(s) referred

require HLA compatibility at the effector phase. This inhibition of HIV replication is mediated by soluble factor(s) referred JOURNAL OF VIROLOGY, May 2000, p. 4456 4464 Vol. 74, No. 10 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. CD8 -Cell Antiviral Factor Activity Is Not Restricted

More information

Significance of the MHC

Significance of the MHC CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ

More information

Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma

Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma Excerpt from MACS&more Vol 8 1/2004 Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma L. Davis Lupo and Salvatore T. Butera HIV and Retrovirology Branch,

More information

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow

More information

DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS

DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS The definitions below are intended as general concepts. There will be exceptions to these general definitions. These definitions do not imply any specific

More information

CHAPTER 3 LABORATORY PROCEDURES

CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified

More information

Transplantation. Immunology Unit College of Medicine King Saud University

Transplantation. Immunology Unit College of Medicine King Saud University Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the

More information

Antigen-Specific b-chemokine Production and CD8 + T-Cell Noncytotoxic Antiviral Activity in HIV-2-Infected Individuals

Antigen-Specific b-chemokine Production and CD8 + T-Cell Noncytotoxic Antiviral Activity in HIV-2-Infected Individuals Antigen-Specific b-chemokine Production and CD8 + T-Cell Noncytotoxic Antiviral Activity in HIV-2-Infected Individuals R. K. S. Ahmed*, H. Norrgreny, Z.daSilvaz, A.Blaxhult,E.-L.Fredriksson{, G. Biberfeld*,

More information

Significance of the MHC

Significance of the MHC CHAPTER 8 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ

More information

10/18/2012. A primer in HLA: The who, what, how and why. What?

10/18/2012. A primer in HLA: The who, what, how and why. What? A primer in HLA: The who, what, how and why What? 1 First recognized in mice during 1930 s and 1940 s. Mouse (murine) experiments with tumors Independent observations were made in humans with leukoagglutinating

More information

Nature Medicine: doi: /nm.2109

Nature Medicine: doi: /nm.2109 HIV 1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs Christoph C. Carter, Adewunmi Onafuwa Nuga, Lucy A. M c Namara, James Riddell IV, Dale Bixby, Michael

More information

The Major Histocompatibility Complex (MHC)

The Major Histocompatibility Complex (MHC) The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens

More information

MATERIALS AND METHODS. (MIP-1 and MIP-1 ), and RANTES (regulated on activation, levels of -chemokines, which play a significant role in

MATERIALS AND METHODS. (MIP-1 and MIP-1 ), and RANTES (regulated on activation, levels of -chemokines, which play a significant role in Proc. Natl. Acad. Sci. USA Vol. 93, pp. 14076 14081, November 1996 Medical Sciences HIV replication in CD4 T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects

More information

Antibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center

Antibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,

More information

An Evolutionary Story about HIV

An Evolutionary Story about HIV An Evolutionary Story about HIV Charles Goodnight University of Vermont Based on Freeman and Herron Evolutionary Analysis The Aids Epidemic HIV has infected 60 million people. 1/3 have died so far Worst

More information

Suppression of HIV replication in the resting CD4 T cell reservoir by autologous CD8

Suppression of HIV replication in the resting CD4 T cell reservoir by autologous CD8 Suppression of HIV replication in the resting CD4 T cell reservoir by autologous CD8 T cells: Implications for the development of therapeutic strategies Tae-Wook Chun*, J. Shawn Justement, Susan Moir,

More information

Treatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques

Treatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques SUPPORTING INFORMATION FOR: Treatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques Lia Vassena, 1,2 Huiyi Miao, 1 Raffaello Cimbro,

More information

Human Immunodeficiency Virus

Human Immunodeficiency Virus Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease

More information

Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers

Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers JOURNAL OF VIROLOGY, Sept. 2011, p. 9646 9650 Vol. 85, No. 18 0022-538X/11/$12.00 doi:10.1128/jvi.05327-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Inhibition of HIV-1 Integration

More information

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer VIRAL TITER COUNTS The best methods of measuring infectious lentiviral titer FLUORESCENCE CYCLES qpcr of Viral RNA SUMMARY Viral vectors are now routinely used for gene transduction in a wide variety of

More information

Documentation of Changes to EFI Standards: v 5.6.1

Documentation of Changes to EFI Standards: v 5.6.1 Modified Standard B - PERSONNEL QUALIFICATIONS B1.000 The laboratory must employ one or more individuals who meet the qualifications and fulfil the responsibilities of the Director/Co-Director, Technical

More information

LYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS

LYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS LYMPHOCYTES & IMMUNOGLOBULINS Dr Mere Kende, Lecturer SMHS Immunity Immune- protection against dangers of non-self/invader eg organism 3 components of immune system 1 st line: skin/mucosa/cilia/hair/saliva/fatty

More information

Significance of the MHC

Significance of the MHC CHAPTER 8 Major Histocompatibility Complex (MHC) What is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) - MHC molecules were initially discovered during studies aimed

More information

Chapter 7 Conclusions

Chapter 7 Conclusions VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION ` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows

More information

RAISON D ETRE OF THE IMMUNE SYSTEM:

RAISON D ETRE OF THE IMMUNE SYSTEM: RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense

More information

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC

More information

Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005)

Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005) Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005) Stephen Spellman Research Manager NMDP Scientific Services Maria Brown Scientific Services Specialist Data Management Conference 2007 1

More information

The Human Major Histocompatibility Complex

The Human Major Histocompatibility Complex The Human Major Histocompatibility Complex 1 Location and Organization of the HLA Complex on Chromosome 6 NEJM 343(10):702-9 2 Inheritance of the HLA Complex Haplotype Inheritance (Family Study) 3 Structure

More information

Viral Genetics. BIT 220 Chapter 16

Viral Genetics. BIT 220 Chapter 16 Viral Genetics BIT 220 Chapter 16 Details of the Virus Classified According to a. DNA or RNA b. Enveloped or Non-Enveloped c. Single-stranded or double-stranded Viruses contain only a few genes Reverse

More information

Varsha Shridhar 1,2, Yue Chen 2 and Phalguni Gupta 2*

Varsha Shridhar 1,2, Yue Chen 2 and Phalguni Gupta 2* Shridhar et al. Virology Journal 214, 11:13 RESEARCH The CD8 Antiviral Factor (CAF) can suppress HIV-1 transcription from the Long Terminal Repeat (LTR) promoter in the absence of elements upstream of

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

The MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK

The MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK The MHC and Transplantation Brendan Clark Transplant Immunology, St James s University Hospital, Leeds, UK Blood Groups Immunofluorescent staining has revealed blood group substance in the cell membranes

More information

Definition of an Epitope on NS3 Recognized by Human CD4 Cytotoxic T Lymphocyte Clones Cross-Reactive for Dengue Virus Types 2, 3, and 4

Definition of an Epitope on NS3 Recognized by Human CD4 Cytotoxic T Lymphocyte Clones Cross-Reactive for Dengue Virus Types 2, 3, and 4 VIROLOGY 240, 169 174 (1998) ARTICLE NO. VY978925 Definition of an Epitope on NS3 Recognized by Human CD4 Cytotoxic T Lymphocyte Clones Cross-Reactive for Dengue Virus Types 2, 3, and 4 Ichiro Kurane,*

More information

Slow Human Immunodeficiency Virus (HIV) Infectivity Correlated with Low HIV Coreceptor Levels

Slow Human Immunodeficiency Virus (HIV) Infectivity Correlated with Low HIV Coreceptor Levels CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Sept. 2001, p. 932 936 Vol. 8, No. 5 1071-412X/01/$04.00 0 DOI: 10.1128/CDLI.8.5.932 936.2001 Copyright 2001, American Society for Microbiology. All Rights

More information

Induction and Clearance of Latent HIV Infection:

Induction and Clearance of Latent HIV Infection: 214 Towards an HIV Cure symposium Melbourne Induction and Clearance of Latent HIV Infection: an Ex-Vivo Assessment of Immune Effectors using Cells from ART-treated Patients DM Margolis 1, C Garrido 1,

More information

Animal hosts Natural host Laboratory animals Rabbits Mice Rats Hamsters Newborn or suckling rodents Animal models for viral pathogenesis 4 Growth of v

Animal hosts Natural host Laboratory animals Rabbits Mice Rats Hamsters Newborn or suckling rodents Animal models for viral pathogenesis 4 Growth of v Principles of Virology Department of Molecular Genetics & Microbiology Univ ersity of Florida, Gainesv ille, FL 1 Outline Virus cultivation Assay of viruses Virus genetics 2 Virus isolation Evidence of

More information

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.

More information

VIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON

VIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON VIRUSES Biology Applications Control David R. Harper GS Garland Science Taylor & Francis Group NEW YORK AND LONDON vii Chapter 1 Virus Structure and 2.2 VIRUS MORPHOLOGY 26 Infection 1 2.3 VIRAL CLASSIFICATION

More information

staining and flow cytometry

staining and flow cytometry Detection of influenza virus-specific T cell responses by intracellular by cytokine intracellular staining cytokine staining and flow cytometry Detection of influenza virus-specific T cell responses and

More information

Isolation, Propagation, and Titration of Human Immunodeficiency Virus Type 1 From Peripheral Blood of Infected Individuals

Isolation, Propagation, and Titration of Human Immunodeficiency Virus Type 1 From Peripheral Blood of Infected Individuals Isolation of HIV-1 From PBMC of Infected Individuals 17 2 Isolation, Propagation, and Titration of Human Immunodeficiency Virus Type 1 From Peripheral Blood of Infected Individuals Hanneke Schuitemaker

More information

Xenotransplantation. Pig as an organ donor

Xenotransplantation. Pig as an organ donor Xenotransplantation Pig as an organ donor Xenotransplantation Transplantation of solid organs Heart, Kidney, Liver Transplantation of live animal cells Pig neuronal and pig pancreatic islet cells Use of

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve

More information

Transplant Types. Basic Concepts of Transplantation Immunology. M. Sue Leffell, PhD. Professor Of Medicine & Director Immunogenetics Laboratory

Transplant Types. Basic Concepts of Transplantation Immunology. M. Sue Leffell, PhD. Professor Of Medicine & Director Immunogenetics Laboratory Basic Concepts of Transplantation Immunology M. Sue Leffell, PhD Professor Of Medicine & Director Immunogenetics Laboratory Transplant Types Autologous (self to self) Syngeneic (identical twin to twin)

More information

RAISON D ETRE OF THE IMMUNE SYSTEM:

RAISON D ETRE OF THE IMMUNE SYSTEM: RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Adaptive Immunity Innate immunity: (Antigen - nonspecific) defense

More information

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY MATERIAL SUPPLEMENTARY MATERIAL Acetone and methanol fruit extracts of Terminalia paniculata inhibit HIV-1 infection in vitro Ankita Durge a, Pratiksha Jadaun a, Ashish Wadhwani a, Ashish A. Chinchansure b, Madhukar

More information

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a

More information

Citation Acta medica Nagasakiensia. 1991, 36

Citation Acta medica Nagasakiensia. 1991, 36 NAOSITE: Nagasaki University's Ac Title Author(s) Induction of Killer Activity in Per Chemotherapy with Methotrexate, Vin (M-VAC) Taniguchi, Keisuke Citation Acta medica Nagasakiensia. 1991, 36 Issue Date

More information

IMMUNOGENETICS AND TRANSPLANTATION

IMMUNOGENETICS AND TRANSPLANTATION IMMUNOGENETICS AND TRANSPLANTATION WHAT S THE MHC GOT TO DO WITH TRANSPLANTATION? We have learned that the molecules of Class I and II MHC are involved in presenting antigenic peptides to the receptors

More information

Structure and Function of Antigen Recognition Molecules

Structure and Function of Antigen Recognition Molecules MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and

More information

DC-SIGN on B Lymphocytes Is Required For Transmission of HIV-1 to T Lymphocytes

DC-SIGN on B Lymphocytes Is Required For Transmission of HIV-1 to T Lymphocytes DC-SIGN on B Lymphocytes Is Required For Transmission of HIV-1 to T Lymphocytes Giovanna Rappocciolo 1*, Paolo Piazza 1, Craig L. Fuller 1, Todd A. Reinhart 1, Simon C. Watkins 2, David T. Rowe 1, Mariel

More information

Received 29 August 2002/Accepted 3 December 2002

Received 29 August 2002/Accepted 3 December 2002 JOURNAL OF VIROLOGY, Mar. 2003, p. 3099 3118 Vol. 77, No. 5 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.5.3099 3118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Simian-Human

More information

BASIC SCIENCE. Effects of Highly Active Antiretroviral Therapy and Immune Recovery on CD8 + T-Cell Mediated Inhibition of HIV-1 Transcription

BASIC SCIENCE. Effects of Highly Active Antiretroviral Therapy and Immune Recovery on CD8 + T-Cell Mediated Inhibition of HIV-1 Transcription BASIC SCIENCE Effects of Highly Active Antiretroviral Therapy and Immune Recovery on CD8 + T-Cell Mediated Inhibition of HIV-1 Transcription Greg Beaudoin, MSc,* Bilge Diker, MSc,* Jonathan B. Angel, MD,*

More information

The functional CD8 T cell response to HIV becomes type-specific in progressive disease

The functional CD8 T cell response to HIV becomes type-specific in progressive disease The functional CD8 T cell response to HIV becomes type-specific in progressive disease Sang Kyung Lee, Zhan Xu, Judy Lieberman, and Premlata Shankar Center for Blood Research and Department of Pediatrics,

More information

Association of HLA-DRB alleles and pulmonary tuberculosis in North Chinese patients

Association of HLA-DRB alleles and pulmonary tuberculosis in North Chinese patients Association of HLA-DRB alleles and pulmonary tuberculosis in North Chinese patients G.L. Shi, X.L. Hu, L. Yang, C.L. Rong, Y.L. Guo and C.X. Song Department of Clinical Immunology Laboratory, Beijing Tuberculosis

More information

Basel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva

Basel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Basel - 6 eptember 2012 J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Outline the HLA system is (a) complex anti-hla immunisation and alloreactivity

More information

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be

More information

Appendix E1. Epidemiology

Appendix E1. Epidemiology Appendix E1 Epidemiology Viruses are the most frequent cause of human infectious diseases and are responsible for a spectrum of illnesses ranging from trivial colds to fatal immunoimpairment caused by

More information

The Role of B Cell Follicles in HIV Replication and Persistence

The Role of B Cell Follicles in HIV Replication and Persistence The Role of B Cell ollicles in HIV Replication and Persistence Elizabeth Connick, M.D. Professor of Medicine Chief, Division of Infectious Diseases University of Arizona July 17, 2016 IAS 2016 Towards

More information

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,

More information

6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?

6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD? 6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.

More information

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Clinical Transplantation Laboratory (CTL) 3rd Floor Tower Wing Guy's Hospital SE9 1RT Contact: Jeremy Skinner Tel: +44 (0)2071881713 E-Mail:

More information

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared

More information

Immunology Lecture 4. Clinical Relevance of the Immune System

Immunology Lecture 4. Clinical Relevance of the Immune System Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor

More information

Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza

Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii Ringworm fungus HIV Influenza Candida Staph aureus Mycobacterium tuberculosis Listeria Salmonella Streptococcus Levels

More information

PMC ATM and ATR activities maintain replication fork integrity during SV40 chromatin replication. PLoS Pathog. 2013;9(4):e PMC

PMC ATM and ATR activities maintain replication fork integrity during SV40 chromatin replication. PLoS Pathog. 2013;9(4):e PMC Class Date Instructors Topic Papers Scott Hensley and Jianxin You Vaccine Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. 2016 Jul 28;166(3):609 23. doi:10.1016/j.cell.2016.06.043.

More information

Production of Interferon Alpha by Dengue Virus-infected Human Monocytes

Production of Interferon Alpha by Dengue Virus-infected Human Monocytes J. gen. Virol. (1988), 69, 445-449. Printed in Great Britain 445 Key words: IFN-ct/dengue virus/monocytes Production of Interferon Alpha by Dengue Virus-infected Human Monocytes By ICHIRO KURANE AND FRANCIS

More information

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD

More information

Micro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people

Micro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people Micro 301 HIV/AIDS Shiu-Lok Hu hus@uw.edu December 3, 2012 Since its discovery 31 years ago Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people In 2011 34.0 million [31.4 35.9 million]

More information

McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells

McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells Effects of McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells X.C. Wei, D.D. Yang, X.R. Han, Y.A. Zhao, Y.C. Li, L.J. Zhang and J.J. Wang Institute of hematological research,

More information

HIV Anti-HIV Neutralizing Antibodies

HIV Anti-HIV Neutralizing Antibodies ,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious

More information

Received 4 December 2001/Accepted 29 April 2002

Received 4 December 2001/Accepted 29 April 2002 JOURNAL OF VIROLOGY, Aug. 2002, p. 8433 8445 Vol. 76, No. 16 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.16.8433 8445.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. The Relationship

More information

Changes in CD4+ cells mirna expression following exposure to HIV 1 Claudio Casoli

Changes in CD4+ cells mirna expression following exposure to HIV 1 Claudio Casoli Changes in CD4+ cells mirna expression following exposure to HIV 1 Claudio Casoli University of Milan Rationale There is evidence that mirnas can modulate host innate immunity against viruses. Specifically

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information

the HLA complex Hanna Mustaniemi,

the HLA complex Hanna Mustaniemi, the HLA complex Hanna Mustaniemi, 28.11.2007 The Major Histocompatibility Complex Major histocompatibility complex (MHC) is a gene region found in nearly all vertebrates encodes proteins with important

More information

1. Overview of Adaptive Immunity

1. Overview of Adaptive Immunity Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information

IN VIVO STUDIES ON VIRAL VIRULENCE

IN VIVO STUDIES ON VIRAL VIRULENCE IN VIVO STUDIES ON VIRAL VIRULENCE M.Phil student: Emily TSUI Supervisor: Professor Paul K.S Chan Department of Microbiology, CUHK Date: 15th Dec, 2014 Viral Virulence Capacity of a virus to cause disease

More information

Brief Definitive Report

Brief Definitive Report Published Online: 1 May, 1988 Supp Info: http://doi.org/10.1084/jem.167.5.1749 Downloaded from jem.rupress.org on January 6, 2019 Brief Definitive Report VIRUS-TRIGGERED IMMUNE SUPPRESSION IN MICE CAUSED

More information

Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells

Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells Gavin M. Mason, Sarah Jackson, Georgina Okecha, Emma Poole, J. G. Patrick Sissons, John Sinclair,

More information

Identification of Microbes Lecture: 12

Identification of Microbes Lecture: 12 Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected

More information

7.014 Problem Set 7 Solutions

7.014 Problem Set 7 Solutions MIT Department of Biology 7.014 Introductory Biology, Spring 2005 7.014 Problem Set 7 Solutions Question 1 Part A Antigen binding site Antigen binding site Variable region Light chain Light chain Variable

More information

Profiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009

Profiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009 Profiling HLA motifs by large scale peptide sequencing 2009 Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009 HLA Background The human leukocyte antigen system (HLA) is the

More information

Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses

Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses Elissa J. Schwartz Associate Professor School of Biological Sciences Department of Mathematics & Statistics Washington

More information

Immune system. Aims. Immune system. Lymphatic organs. Inflammation. Natural immune system. Adaptive immune system

Immune system. Aims. Immune system. Lymphatic organs. Inflammation. Natural immune system. Adaptive immune system Aims Immune system Lymphatic organs Inflammation Natural immune system Adaptive immune system Major histocompatibility complex (MHC) Disorders of the immune system 1 2 Immune system Lymphoid organs Immune

More information

Received 31 March 2011/Accepted 19 July 2011

Received 31 March 2011/Accepted 19 July 2011 JOURNAL OF VIROLOGY, Oct. 2011, p. 10518 10528 Vol. 85, No. 20 0022-538X/11/$12.00 doi:10.1128/jvi.00655-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Fitness Costs and Diversity

More information

Risks and Management of SIV in De Brazza Guenon (Cercopithecus neglectus)

Risks and Management of SIV in De Brazza Guenon (Cercopithecus neglectus) Risks and Management of SIV in De Brazza Guenon (Cercopithecus neglectus) NB: This paper is produced specifically for SIV in De Brazza Monkeys. There are significant species differences and therefore the

More information

HIV Diagnostic Testing

HIV Diagnostic Testing In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk

More information

T-Pharmacytes for the Targeted Eradication of HIV Reservoirs

T-Pharmacytes for the Targeted Eradication of HIV Reservoirs T-Pharmacytes for the Targeted Eradication of HIV Reservoirs Walker Lab Rachel O Connor Alicja Trocha Dan Karel Irvine Lab Stefanie Mueller Humanized Mouse Core Vlad Vrbanac Andy Tager Todd Allen Darrell

More information

SUPPLEMENTARY INFORMATION. Divergent TLR7/9 signaling and type I interferon production distinguish

SUPPLEMENTARY INFORMATION. Divergent TLR7/9 signaling and type I interferon production distinguish SUPPLEMENTARY INFOATION Divergent TLR7/9 signaling and type I interferon production distinguish pathogenic and non-pathogenic AIDS-virus infections Judith N. Mandl, Ashley P. Barry, Thomas H. Vanderford,

More information

It takes more than just a single target

It takes more than just a single target It takes more than just a single target As the challenges you face evolve... HIV mutates No HIV-1 mutation can be considered to be neutral 1 Growing evidence indicates all HIV subtypes may be prone to

More information

ALTHOUGH disease develops within 10 years in

ALTHOUGH disease develops within 10 years in 228 THE NEW ENGLAND JOURNAL OF MEDICINE Jan. 26, 1995 BRIEF REPORT: ABSENCE OF INTACT nef SEQUENCES IN A LONG-TERM SURVIVOR WITH NONPROGRESSIVE HIV-1 INFECTION FRANK KIRCHHOFF, PH.D., THOMAS C. GREENOUGH,

More information

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES 1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.

More information

Therapeutic Cancer Vaccines

Therapeutic Cancer Vaccines Therapeutic Cancer Vaccines Goal for all therapeutic cancer vaccines: To enhance the natural immune response so that it becomes an effective therapy Approaches being investigated in clinical studies: Whole

More information